Literature DB >> 8585296

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix.

B Rönnberg, M Fekadu, B Morein.   

Abstract

It is well established that ISCOMs function efficiently as an antigen-presenting system and protective immunity has been evoked against a variety of infectious agents. The built-in saponin adjuvant from Quillaja saponaria Molina is responsible for the strong immunoenhancing activity displayed by the ISCOM. However, to allow the use of ISCOMs in human vaccines it is necessary to determine the immunological properties and toxicity of chemically defined Quillaja components. Thus, the present study was carried out in a mouse model to determine the adjuvant activity and toxicity of "free", isolated Quillaja components, as well as formulated into particles, i.e. ISCOM matrix. The purified Quillaja components and the ISCOM matrix formulations were examined for their adjuvant activity in a model system consisting of purified influenza virus antigen and Quillaja saponins. It was demonstrated that a Quillaja component, designated QH-C, either as a "free" component or in an ISCOM matrix, has a strong adjuvant activity, but little or no toxicity in the doses tested. In addition, QH-C in the form of ISCOM matrix does not induce any local reactions at the site of injection. Thus, ISCOMs containing the QH-C component, devoid of toxicity, but with strong adjuvant activity, can prove to be useful in adjuvant formulations for human use.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585296     DOI: 10.1016/0264-410x(95)00105-a

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity.

Authors:  Nikolai Petrovsky
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

2.  Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.

Authors:  Karen White; Thomas Rades; Philip Kearns; Istvan Toth; Sarah Hook
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

3.  Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.

Authors:  Michael M Lieberman; David E Clements; Steven Ogata; Gordon Wang; Gloria Corpuz; Teri Wong; Tim Martyak; Lynne Gilson; Beth-Ann Coller; Julia Leung; Douglas M Watts; Robert B Tesh; Marina Siirin; Amelia Travassos da Rosa; Tom Humphreys; Carolyn Weeks-Levy
Journal:  Vaccine       Date:  2006-08-30       Impact factor: 3.641

Review 4.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Immunogenicity and Reactogenicity in Q Fever Vaccine Development.

Authors:  Alycia P Fratzke; Erin J van Schaik; James E Samuel
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

6.  The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.

Authors:  K F Hu; M Elvander; M Merza; L Akerblom; A Brandenburg; B Morein
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

7.  Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index.

Authors:  Kefei Hu; Saideh Berenjian; Rolf Larsson; Joachim Gullbo; Peter Nygren; Tanja Lövgren; Bror Morein
Journal:  Int J Nanomedicine       Date:  2010-02-02

8.  Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy.

Authors:  Teresa Cruz-Bustos; Gloria González-González; Julia Morales-Sanfrutos; Alicia Megía-Fernández; Francisco Santoyo-González; Antonio Osuna
Journal:  Int J Nanomedicine       Date:  2012-12-03

Review 9.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

Review 10.  Novel adjuvants & delivery vehicles for vaccines development: a road ahead.

Authors:  Teena Mohan; Priyanka Verma; D Nageswara Rao
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.